You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRemifentanil
Accession NumberDB00899  (APRD01216)
TypeSmall Molecule
GroupsApproved
DescriptionRemifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist. Hence, it causes a reduction in sympathetic nervous system tone, respiratory depression and analgesia.
Structure
Thumb
Synonyms
REMIFENTANIL
Remifentanyl
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Remifentanil for Injectionpowder for solution2 mgintravenousTeva Canada LimitedNot applicableNot applicableCanada
Remifentanil for Injectionpowder for solution1 mgintravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Remifentanil for Injectionpowder for solution1 mgintravenousTeva Canada LimitedNot applicableNot applicableCanada
Remifentanil for Injectionpowder for solution2 mgintravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Remifentanil Hydrochloride for Injectionpowder for solution5 mgintravenousSterimax IncNot applicableNot applicableCanada
Remifentanil Hydrochloride for Injectionpowder for solution1 mgintravenousSterimax Inc2011-09-27Not applicableCanada
Remifentanil Hydrochloride for Injectionpowder for solution2 mgintravenousSterimax Inc2011-09-29Not applicableCanada
Ultivainjection, powder, lyophilized, for solution1 mg/mLintravenousMylan Institutional LLC1996-11-06Not applicableUs
Ultivapowder for solution2 mgintravenousAbbvie Corporation1997-04-072013-10-02Canada
Ultivapowder for solution5 mgintravenousAbbvie Corporation1997-03-172013-10-02Canada
Ultivapowder for solution1 mgintravenousAbbvie Corporation1997-04-072013-10-02Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Remifentanil hydrochloride
ThumbNot applicableDBSALT001450
Categories
UNIIP10582JYYK
CAS number132875-61-7
WeightAverage: 376.4467
Monoisotopic: 376.199822016
Chemical FormulaC20H28N2O5
InChI KeyInChIKey=ZTVQQQVZCWLTDF-UHFFFAOYSA-N
InChI
InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3
IUPAC Name
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-phenylpropanamido)piperidine-4-carboxylate
SMILES
CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acids and derivatives
Alternative Parents
Substituents
  • Alpha-amino acid or derivatives
  • Anilide
  • Piperidinecarboxylic acid
  • 4-aminopiperidine
  • Benzenoid
  • Piperidine
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Methyl ester
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor use during the induction and maintenance of general anesthesia.
PharmacodynamicsRemifentanil is an opioid agonist with rapid onset and peak effect and ultra-short duration of action. The opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone. The analgesic effects of remifentanil are rapid in onset and offset. Its effects and side effects are dose dependent and similar to other opioids. Remifentanil in humans has a rapid blood-brain equilibration half-time of 1 ± 1 minutes (mean ± SD) and a rapid onset of action.
Mechanism of actionRemifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 350 mL/kg
  • 452 ± 144 mL/kg [neonates]
  • 223 ± 30.6 mL/kg [adolescents]
Protein binding70% (bound to plasma proteins)
Metabolism

By hydrolysis of the propanoic acid-methyl ester linkage by nonspecific blood and tissue esterases.

Route of eliminationRemifentanil is an esterase-metabolized opioid. The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination half-life of approximately 90 minutes.
Half life1-20 minutes
Clearance
  • 40 mL/min/kg [young, healthy adults]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Remifentanil Action PathwayDrug actionSMP00416
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6136
Blood Brain Barrier+0.9381
Caco-2 permeable-0.5271
P-glycoprotein substrateSubstrate0.7345
P-glycoprotein inhibitor IInhibitor0.8682
P-glycoprotein inhibitor IINon-inhibitor0.6428
Renal organic cation transporterNon-inhibitor0.7077
CYP450 2C9 substrateNon-substrate0.8041
CYP450 2D6 substrateNon-substrate0.8786
CYP450 3A4 substrateSubstrate0.6963
CYP450 1A2 substrateNon-inhibitor0.9355
CYP450 2C9 inhibitorNon-inhibitor0.8788
CYP450 2D6 inhibitorNon-inhibitor0.8838
CYP450 2C19 inhibitorNon-inhibitor0.8201
CYP450 3A4 inhibitorNon-inhibitor0.7827
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7945
Ames testNon AMES toxic0.7388
CarcinogenicityNon-carcinogens0.8554
BiodegradationNot ready biodegradable0.9428
Rat acute toxicity2.6994 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Inhibitor0.6126
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bioniche teoranta
Packagers
Dosage forms
FormRouteStrength
Powder for solutionintravenous1 mg
Powder for solutionintravenous2 mg
Injection, powder, lyophilized, for solutionintravenous1 mg/mL
Powder for solutionintravenous5 mg
Prices
Unit descriptionCostUnit
Ultiva 5 mg vial118.15USD vial
Ultiva 2 mg vial57.2USD vial
Ultiva 1 mg vial30.19USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5019583 No1993-07-122010-07-12Us
US5866591 Yes1998-03-102018-03-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.591 mg/mLALOGPS
logP1.75ALOGPS
logP1.52ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)7.51ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area76.15 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity100.56 m3·mol-1ChemAxon
Polarizability40.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Jacob Mathew, J. Killgore, “New methods for the synthesis of alfentanil, sufentanil, and remifentanil.” U.S. Patent US20060149071, issued July 06, 2006.

US20060149071
General ReferencesNot Available
External Links
ATC CodesN01AH06
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (380 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Remifentanil.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Remifentanil.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Remifentanil.
AcepromazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Remifentanil.
adipiplonThe risk or severity of adverse effects can be increased when Remifentanil is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Remifentanil.
AlimemazineAlimemazine may increase the hypotensive activities of Remifentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Remifentanil.
AlvimopanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Remifentanil which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amobarbital.
AmoxapineRemifentanil may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Remifentanil.
AmperozideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Remifentanil.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Remifentanil.
AripiprazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Asenapine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Remifentanil.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Remifentanil.
AzaperoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azaperone.
AzelastineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Remifentanil.
AzosemideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Remifentanil.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Remifentanil.
BenzocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Remifentanil.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benzyl alcohol.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Remifentanil.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
BrimonidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Remifentanil.
BuprenorphineBuprenorphine may decrease the analgesic activities of Remifentanil.
BuprenorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Remifentanil.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Remifentanil.
ButacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Remifentanil.
ButorphanolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Remifentanil is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Remifentanil.
CarbinoxamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Remifentanil.
ChlormezanoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Remifentanil.
ChlorphentermineChlorphentermine may increase the analgesic activities of Remifentanil.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Remifentanil.
ChlorpromazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Remifentanil.
CitalopramRemifentanil may increase the serotonergic activities of Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with clomethiazole.
ClomipramineRemifentanil may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Remifentanil.
ClonazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Remifentanil.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Remifentanil.
CocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Remifentanil.
ConivaptanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Conivaptan.
CyclizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Remifentanil.
CyclothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remifentanil.
DapoxetineRemifentanil may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Remifentanil.
deramciclaneThe risk or severity of adverse effects can be increased when Remifentanil is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Remifentanil.
DesmopressinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Remifentanil.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Remifentanil.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Remifentanil.
DextromoramideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Remifentanil.
DezocineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Remifentanil.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Remifentanil.
DifenoxinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
DoxylamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Remifentanil is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Remifentanil.
DrospirenoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Remifentanil.
EcgonineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Remifentanil is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efonidipine.
EluxadolineRemifentanil may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Remifentanil.
EntacaponeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Entacapone.
EplerenoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Eplerenone.
EscitalopramRemifentanil may increase the serotonergic activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Remifentanil.
Etacrynic acidThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etacrynic acid.
EthanolRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Remifentanil.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remifentanil.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Remifentanil.
EthosuximideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Remifentanil.
EtoperidoneRemifentanil may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fencamfamine.
FenfluramineRemifentanil may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Remifentanil.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Remifentanil.
FexofenadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flunitrazepam.
FluoxetineRemifentanil may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Remifentanil.
FluphenazineFluphenazine may increase the hypotensive activities of Remifentanil.
FluphenazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Remifentanil.
FluspirileneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluticasone Propionate.
FluvoxamineRemifentanil may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Remifentanil.
FosphenytoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Remifentanil is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Remifentanil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Remifentanil.
GuanfacineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Remifentanil.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Remifentanil.
HalothaneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Remifentanil.
HexobarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Remifentanil.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydrocodone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Remifentanil.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Remifentanil.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
HydroxyzineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Remifentanil.
IloperidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Imipramine.
IndalpineRemifentanil may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Indapamide.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Remifentanil.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Remifentanil.
IsosorbideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Isosorbide.
KetamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketobemidone.
KW-3902The risk or severity of adverse effects can be increased when Remifentanil is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levomethadyl Acetate.
LevomilnacipranRemifentanil may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Remifentanil.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Remifentanil.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Remifentanil.
LithiumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Remifentanil.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Remifentanil.
Lu AA21004Remifentanil may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Remifentanil.
LurasidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Remifentanil.
MeclizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Remifentanil is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Remifentanil.
MepivacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remifentanil.
MersalylThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Remifentanil.
MesoridazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Remifentanil.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Remifentanil.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Remifentanil.
MethapyrileneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Remifentanil.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Remifentanil.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Remifentanil.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Remifentanil.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Remifentanil.
MetolazoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metolazone.
MetyrosineRemifentanil may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Remifentanil.
MilnacipranRemifentanil may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
MirtazapineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Remifentanil.
MolindoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Remifentanil.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Remifentanil.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Remifentanil.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
NabiloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nabilone.
NalbuphineNalbuphine may decrease the analgesic activities of Remifentanil.
NalbuphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Remifentanil can be decreased when used in combination with Naltrexone.
NitrazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Remifentanil.
OlanzapineRemifentanil may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Remifentanil.
OlopatadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Opium.
OrphenadrineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Remifentanil.
OsanetantThe risk or severity of adverse effects can be increased when Remifentanil is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Remifentanil.
OxprenololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Remifentanil.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Remifentanil.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Remifentanil.
OxymorphoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Remifentanil.
PaliperidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Remifentanil.
ParaldehydeRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Remifentanil.
ParoxetineRemifentanil may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Remifentanil.
PentazocinePentazocine may decrease the analgesic activities of Remifentanil.
PentazocineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Remifentanil.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Remifentanil.
PerampanelThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Remifentanil.
PerphenazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Remifentanil.
PhenobarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Remifentanil.
PhenytoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Remifentanil.
PipotiazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Remifentanil.
PiretanideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pomalidomide.
PotassiumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium Citrate.
PramipexoleRemifentanil may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Remifentanil.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Remifentanil.
PrimidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Remifentanil.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Remifentanil.
ProchlorperazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Remifentanil.
PromazinePromazine may increase the hypotensive activities of Remifentanil.
PromazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Remifentanil.
PromethazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Remifentanil.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Remifentanil.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Remifentanil.
PropoxycaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Remifentanil is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Remifentanil.
RamelteonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ramelteon.
RamosetronRemifentanil may increase the constipating activities of Ramosetron.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Remifentanil.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Remifentanil.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Remifentanil.
RomifidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Romifidine.
RopiniroleRemifentanil may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Remifentanil.
RotigotineRemifentanil may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Remifentanil.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Remifentanil is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Remifentanil.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Remifentanil.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Remifentanil.
SertindoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sertindole.
SertralineRemifentanil may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Remifentanil.
SpironolactoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Remifentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Remifentanil.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Remifentanil.
SuvorexantThe risk or severity of adverse effects can be increased when Remifentanil is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Remifentanil.
TetrabenazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrodotoxin.
ThalidomideRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Remifentanil.
TheobromineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Remifentanil.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Remifentanil.
ThioridazineThioridazine may increase the hypotensive activities of Remifentanil.
ThioridazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiagabine.
TicrynafenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Remifentanil.
TizanidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Remifentanil.
TolvaptanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Remifentanil.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Remifentanil.
TrazodoneRemifentanil may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Remifentanil.
TriamtereneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Remifentanil.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Remifentanil.
TrifluoperazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Remifentanil.
TriflupromazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Remifentanil.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Remifentanil.
TrimipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Remifentanil.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Remifentanil.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Remifentanil.
UlaritideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Remifentanil.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Remifentanil.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Remifentanil.
VigabatrinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Vigabatrin.
VilazodoneRemifentanil may increase the serotonergic activities of Vilazodone.
VortioxetineRemifentanil may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Remifentanil.
XylazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ziconotide.
ZimelidineRemifentanil may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Remifentanil.
ZolazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Remifentanil.
ZonisamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823. [PubMed:16114980 ]
  2. Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia. CNS Drugs. 2005;19(12):1069-74. [PubMed:16332149 ]
  3. Warner DS, Hindman BJ, Todd MM, Sawin PD, Kirchner J, Roland CL, Jamerson BD: Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Anesth Analg. 1996 Aug;83(2):348-53. [PubMed:8694317 ]
  4. Guy J, Hindman BJ, Baker KZ, Borel CO, Maktabi M, Ostapkovich N, Kirchner J, Todd MM, Fogarty-Mack P, Yancy V, Sokoll MD, McAllister A, Roland C, Young WL, Warner DS: Comparison of remifentanil and fentanyl in patients undergoing craniotomy for supratentorial space-occupying lesions. Anesthesiology. 1997 Mar;86(3):514-24. [PubMed:9066316 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Hoke JF, Cunningham F, James MK, Muir KT, Hoffman WE: Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther. 1997 Apr;281(1):226-32. [PubMed:9103501 ]
  7. Patel SS, Spencer CM: Remifentanil. Drugs. 1996 Sep;52(3):417-27; discussion 428. [PubMed:8875131 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Stucke AG, Zuperku EJ, Sanchez A, Tonkovic-Capin M, Tonkovic-Capin V, Mustapic S, Stuth EA: Opioid receptors on bulbospinal respiratory neurons are not activated during neuronal depression by clinically relevant opioid concentrations. J Neurophysiol. 2008 Nov;100(5):2878-88. doi: 10.1152/jn.90620.2008. Epub 2008 Sep 24. [PubMed:18815346 ]
  2. Rodrigues AR, Castro MS, Francischi JN, Perez AC, Duarte ID: Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats. Braz J Med Biol Res. 2005 Jan;38(1):91-7. Epub 2005 Jan 18. [PubMed:15665994 ]
  3. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K: Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005 Mar-Apr;13(2):165-74. [PubMed:15828941 ]
  4. Sahin AS, Duman A, Atalik EK, Ogun CO, Sahin TK, Erol A, Ozergin U: The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):197-200. [PubMed:15868528 ]
  5. Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44(12):1279-86. [PubMed:16372825 ]
  6. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006 May;28(5):707-14. [PubMed:16861092 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Wong GT, Li R, Jiang LL, Irwin MG: Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand. 2010 Apr;54(4):510-8. doi: 10.1111/j.1399-6576.2009.02145.x. Epub 2009 Oct 29. [PubMed:19878098 ]
  2. Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, Ko MC: Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology. 2008 May;33(4):478-86. doi: 10.1016/j.psyneuen.2008.01.006. Epub 2008 Mar 5. [PubMed:18325678 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 03:38